NCT04262466 2026-03-06Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsImmunocore LtdPhase 1/2 Active not recruiting410 enrolled
NCT07131345 2025-08-20Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant MesotheliomaNational Cancer Center, ChinaPhase 1/2 Not yet recruiting55 enrolled